At ESMO 2023, pharmaceutical giants including Daiichi Sankyo, Bristol Myers Squibb, AstraZeneca, Revolution Medicines, Jacobio Pharma, Merus, Merck, and more are on the edge of their seats, ready to unveil groundbreaking research on NSCLC in oral and poster presentations. Join us in delving into the exciting glecirasib and JAB-3312 combination therapy trial for KRAS NSCLC!

Jacobio Pharma to Present Phase I/II Data of Glecirasib in Combination with JAB-3312 at the 2023 ESMO Conference

• Abstract Number – #653O
• Abstract Type – Proffered Paper Session
• Indication – Solid tumors
• Target –  KRAS G12C-mutation

Glecirasib is a KRAS G12C inhibitor developed by Jacobio. Several Phase I/II clinical trials of glecirasib are currently ongoing in China, the United States, and Europe for patients with advanced solid tumors harboring KRAS G12C mutation. This includes a pivotal clinical trial in NSCLC in China; a monotherapy study for STK11 co-mutated NSCLC in the front-line setting, and combination therapy trials with SHP2 inhibitor JAB-3312 in NSCLC and with Cetuximab in colorectal cancer.

Studies have shown that SHP2 inhibitor is one of the most optimal partners for KRAS G12C inhibitor in NSCLC. Jacobio previously presented preclinical results of the above combination at the 2022 ESMO Asia Congress, demonstrating the combination of JAB-21822 and JAB-3122 synergistically inhibited tumor growth in multiple KRAS G12C inhibitor-resistant models. 

As of April 2023, in the Phase I/II study the drug combo was well tolerated. The ORR of 50% and DCR of 100% were observed in patients with KRAS G12Ci naïve NSCLC, and in patients with treated KRAS G12Ci NSCLC the ORR and DCR were 14.3% and 57.1% respectively. This suggests that the combination of JAB-21822 and JAB-3312 may overcome resistance to KRAS G12C inhibitors in cancer patients.

Additional safety, efficacy, and PK data will be discussed at ESMO 2023.

Note: The therapeutics segment is experiencing significant NSCLC clinical trial activity, which is further expected to drive Non-Small Cell Lung Caner market growth in the coming years.